Company Encyclopedia
View More
name
Relmada Therapeutics
RLMD.US
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease.
4.514 T
RLMD.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Mizuho Securities upgrades Relmada Therapeutics (RLMD) to a Buy

    Mizuho Securities analyst Uy Ear upgraded Relmada Therapeutics (RLMD) to a Buy with a price target of $10.00. Despite a general Hold consensus, Ear focuses on the Healthcare sector and has an average return of -1.3% with a 37.82% success rate on stock recommendations.

    Tip Ranks·
    US
    RLMD
    -1.48%
    Tip Ranks·
    US
    RLMD
    -1.48%

    Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success

    Relmada Therapeutics Inc's Q3 earnings call highlighted clinical and financial successes, including a 92% response rate in a Phase Two study for NDV-01, FDA alignment for Phase Three, and a $100 million capital raise. The company reduced operating expenses and appointed Dr. Raj S. Pruthi as Chief Medical Officer. Despite previous cash reserve concerns, the financial infusion supports operations through 2028. Forward guidance includes Phase Three studies for NDV-01 and Phase Two for Sepranolone. Relmada is well-positioned for growth with strategic regulatory alignments and financial stability.

    Tip Ranks·
    US
    RLMD
    -1.48%
    Tip Ranks·
    US
    RLMD
    -1.48%

    Relmada Therapeutics Reports Q3 2025 Financial Results

    Relmada Therapeutics Reports Q3 2025 Financial Results

    Tip Ranks·
    US
    RLMD
    -1.48%
    Tip Ranks·
    US
    RLMD
    -1.48%

    Relmada Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    RLMD
    -1.48%
    LB filings·
    US
    RLMD
    -1.48%

    Relmada Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    RLMD
    -1.48%
    LB filings·
    US
    RLMD
    -1.48%
    © 2025 Longbridge｜Disclaimer